Ten new diagnostic codes were added to private reimbursement schedule in England in January

The Clinical Coding and Schedule Development (CCSD) develops and maintains procedural and diagnostics nomenclature for private payers in England. Once codes are added to the Schedule, a rivate insurance company can develop reimbursement tariff for these procedures and tests.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in January:

• Anti C1Q antibodies (5083B)
• NRAS (genetic suffix G ) (0018G)
• EGFR vIII mutation (genetic suffix G ) (0019G)
• EGFR amplification test using FISH (genetic suffix G ) (0020G)
• H3F3A mutations (genetic suffix G ) (0021G)
• C-MYC Amplification test using FISH. (genetic suffix G ) (0022G)
• BRAF genetic suffix G (0023G)
• Soluble CD25 (5084B)
• ROS1 G suffix (0024G)
• Umbilical Cord Ph Level (5085B)

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.